Terms: = Breast cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802
1840 results:
1. Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells.
Favaretto G; Rossi MN; Cuollo L; Laffranchi M; Cervelli M; Soriani A; Sozzani S; Santoni A; Antonangeli F
Cancer Immunol Immunother; 2024 May; 73(6):113. PubMed ID: 38693312
[TBL] [Abstract] [Full Text] [Related]
2. Pembrolizumab response in stage IV luminal-type breast cancer with high microsatellite instability: a case report.
Inakami K; Fujita N; Iguchi C; Enomoto Y; Minohata J; Sata A; Miyagawa Y; Yanagisawa T; Saitoh T; Nomura T; Sawai Y; Takahara K; Kasugai T; Shiba E
J Med Case Rep; 2024 May; 18(1):214. PubMed ID: 38689362
[TBL] [Abstract] [Full Text] [Related]
3. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
4. Doses to the right coronary artery and the left anterior descending coronary artery and death from ischemic heart disease after breast cancer radiotherapy: a case-control study in a population-based cohort.
Perman M; Johansson KA; Holmberg E; Karlsson P
Acta Oncol; 2024 Apr; 63():240-247. PubMed ID: 38682458
[TBL] [Abstract] [Full Text] [Related]
5. Synthesis, bioactivity assessment, molecular docking and ADMET studies of new chromone congeners exhibiting potent anticancer activity.
Abo-Salem HM; El Souda SSM; Shafey HI; Zoheir KMA; Ahmed KM; Mahmoud K; Mahrous KF; Fawzy NM
Sci Rep; 2024 Apr; 14(1):9636. PubMed ID: 38671055
[TBL] [Abstract] [Full Text] [Related]
6. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving cdk4/6 Inhibitors for Metastatic breast cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract] [Full Text] [Related]
7. Overcoming BRAF and cdk4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.
Park S; Ryu WJ; Kim TY; Hwang Y; Han HJ; Lee JD; Kim GM; Sohn J; Kim SK; Kim MH; Kim J
Exp Mol Med; 2024 Apr; 56(4):987-1000. PubMed ID: 38622197
[TBL] [Abstract] [Full Text] [Related]
8. Predicting drug-drug interactions in breast cancer patients treated with cdk4/6 inhibitors and forward planning.
Kulkarni A; Singh J
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):225-233. PubMed ID: 38600865
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive Transcriptomic Analysis of EWSR1::WT1 Targets Identifies cdk4/6 Inhibitors as an Effective Therapy for Desmoplastic Small Round Cell Tumors.
Magrath JW; Sampath SS; Flinchum DA; Hartono AB; Goldberg IN; Boehling JR; Savkovic SD; Lee SB
Cancer Res; 2024 May; 84(9):1426-1442. PubMed ID: 38588409
[TBL] [Abstract] [Full Text] [Related]
10. Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer.
McGrath MK; Abolhassani A; Guy L; Elshazly AM; Barrett JT; Mivechi NF; Gewirtz DA; Schoenlein PV
Front Endocrinol (Lausanne); 2024; 15():1298423. PubMed ID: 38567308
[TBL] [Abstract] [Full Text] [Related]
11. Estrogen receptor regulation of the immune microenvironment in breast cancer.
McGuinness C; Britt KL
J Steroid Biochem Mol Biol; 2024 Jun; 240():106517. PubMed ID: 38555985
[TBL] [Abstract] [Full Text] [Related]
12. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
Browne IM; André F; Chandarlapaty S; Carey LA; Turner NC
Lancet Oncol; 2024 Apr; 25(4):e139-e151. PubMed ID: 38547898
[TBL] [Abstract] [Full Text] [Related]
13. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM; Han HS; Rugo HS; Stringer-Reasor EM; Specht JM; Dees EC; Kabos P; Suzuki S; Mutka SC; Sullivan BF; Gorbatchevsky I; Wesolowski R
Lancet Oncol; 2024 Apr; 25(4):474-487. PubMed ID: 38547892
[TBL] [Abstract] [Full Text] [Related]
14. A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced breast cancer.
Ardavanis-Loukeris G; Kokkali S; Perdikari K; Karatrasoglou E; Talagani S; Tzovaras A; Ardavanis A
Anticancer Res; 2024 Apr; 44(4):1559-1565. PubMed ID: 38537957
[TBL] [Abstract] [Full Text] [Related]
15. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic breast cancer Harboring Altered PI3K/AKT/mTOR.
Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
[TBL] [Abstract] [Full Text] [Related]
16. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Gómez Tejeda Zañudo J; Barroso-Sousa R; Jain E; Jin Q; Li T; Buendia-Buendia JE; Pereslete A; Abravanel DL; Ferreira AR; Wrabel E; Helvie K; Hughes ME; Partridge AH; Overmoyer B; Lin NU; Tayob N; Tolaney SM; Wagle N
Nat Commun; 2024 Mar; 15(1):2446. PubMed ID: 38503755
[TBL] [Abstract] [Full Text] [Related]
17. A rare case of Takotsubo cardiomyopathy.
Fiste O; Trika C; Syrigos NK; Kotteas EA
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2063-2067. PubMed ID: 38497887
[TBL] [Abstract] [Full Text] [Related]
18. PRMT5 is an actionable therapeutic target in cdk4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
[TBL] [Abstract] [Full Text] [Related]
19. Impact of HER2-low expression on the efficacy of endocrine therapy with or without cdk4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.
Wu Y; Mo H; Xu H; Wang Y; Wang J; Ma F; Xu B
Thorac Cancer; 2024 Apr; 15(12):965-973. PubMed ID: 38480513
[TBL] [Abstract] [Full Text] [Related]
20. Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer.
Hong J; Chen T; Ouyang L; Du N; Li A; Zhou Z; Zhang H; Xia Z; Meng J
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):559-566. PubMed ID: 38470447
[TBL] [Abstract] [Full Text] [Related]
[Next]
